PDT is a minimally invasive treatment that destroys cancer cells with a combination of a photoactive drug known as a photosensitizer and a specific wavelength of light. When the photosensitizers are activated by the laser light, they produce a form of oxygen that destroys nearby cancer cells.

Focusing on using PDT for bone cancer and head-and-neck squamous cell carcinoma, which is a tumor of the mucous membrane, the project will study the delivery and targeting of photosensitizers encapsulated in lipid nano-particles. The cancer models have been selected as models of untreated cancers or cancers with current disabilitating therapies. These carriers offer a high payload that will include antibodies targeting specific tumor biomarkers.

PDT has already shown significant potential for improving cancer treatment because it offers strictly focused application, biocompatibility with other forms of treatment, the option for repeated use, excellent cosmetic or functional outcomes and fast recovery.

But use of PDT for cancer treatment has been restrained by limited effectiveness of the photosensitizers on reaching the tumor and the potential damage to healthy cells near the tumor.

CEA-Leti, which is coordinating this European project, expects the nano carrier-based approach will significantly improve delivery and targeting of the photosensitizer, enhancing concentrations at the tumor site even after systemic application.

The TARGET-PDT project will study all aspects of PDT treatment: nano-carrier size and payload, photosensitizers such as chlorines and phthalocyanines, targeting method and types of laser irradiation.

The experimental approach will be developed into a preclinical validation to deliver an optimised combination for first clinical “nano-PDT” at a later stage. By using nanotechnology-based photosensitizer delivery systems, the project will set the stage for improved control of the therapy and more comfort for cancer patients.

About TARGET-PDT
CEA-Leti is coordinating TARGET-PDT as part of its research program on organic nanocarriers and delivery systems for clinical applications like molecular imaging and drug delivery.
The partnership put together highly complementary partners besides CEA-Leti, such as the European industrial leader in PDT, the German company Biolitec AG, a Swiss university hospital with high reputation in clinical PDT, the University Hospital Zurich, and a French research institute, Centre Alexis Vautrin, specialised in PDT as a therapy for cancer.

Project coordinator:Patrick Boisseau

+33 4 38 78 38 54

patrick.boisseau@cea.fr